Alpha Cognition (Alpha Cognition) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Change In Inventory?

Alpha Cognition's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Alpha Cognition's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Alpha Cognition's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Alpha Cognition's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Alpha Cognition's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Alpha Cognition Change In Inventory Historical Data

The historical data trend for Alpha Cognition's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Change In Inventory Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial										-	-	-	-	-

Alpha Cognition Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Alpha Cognition (OTCPK:ACOGF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Alpha Cognition's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Alpha Cognition's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Alpha Cognition's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Alpha Cognition Change In Inventory Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition (Alpha Cognition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

ACOG:Canada

Address

301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2

Website

https://www.alphacognition.com

Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.